Den kliniske effekt er primært vurderet i non- neutropene patienter med C. albicans- infektioner og i et begrænset antal patienter inficeret med non- albicans, hovedsagelig C. glabrata, C. parapsilosis og C. tropicalis.
Clinical efficacy has been evaluated primarily in non-neutropenic patients with C. albicans infections and in a smaller number of patients infected with non-albicans, mainly C. glabrata, C. parapsilosis and C. tropicalis.